TABLE OF CONTENTS | |||||||||||||||||||||||||||||||||||||
January 2015 Volume 11 Number 1 | |||||||||||||||||||||||||||||||||||||
In this issue
| |||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||
NEWS AND VIEWS | Top | ||||||||||||||||||||||||||||||||||||
Parkinson disease: How reliable are prodromal indicators of Parkinson disease? Laura Silveira-Moriyama & Andrew J. Lees Published online: 16 December 2014 p5 | doi:10.1038/nrneurol.2014.235 The notion that the classic motor features of Parkinson disease (PD) are preceded by a prodrome has received renewed interest in the past decade. A recent study corroborates previous findings that smell loss and constipation are signifiers of nigral degeneration. But can we really predict who is going to get PD? Full Text | PDF | |||||||||||||||||||||||||||||||||||||
Demyelinating disease: Is TOPIC the last trial for clinically isolated syndrome? Bruce A. C. Cree Published online: 16 December 2014 p6 | doi:10.1038/nrneurol.2014.239 The recent TOPIC trial found that teriflunomide could prevent relapses in patients with clinically isolated syndrome (CIS). Many other multiple sclerosis (MS) therapies are effective for CIS, because CIS is the first clinical manifestation of MS for most patients. Questions remain over the utility of future trials like TOPIC. Full Text | PDF | |||||||||||||||||||||||||||||||||||||
Stroke: LDL and stroke risk—clinical practice or target practice? Jong-Ho Park & Bruce Ovbiagele Published online: 09 December 2014 p8 | doi:10.1038/nrneurol.2014.234 LDL-lowering drugs are widely recommended for the secondary prevention of vascular events in patients who have experienced a stroke or transient ischaemic attack. As a new study illustrates, however, lipid management among this group remains inadequate, possibly placing patients at unnecessary risk of stroke recurrence. Full Text | PDF | |||||||||||||||||||||||||||||||||||||
Parkinson disease: Exercise matters in patients with PD—another piece of evidence Georg Ebersbach Published online: 02 December 2014 p9 | doi:10.1038/nrneurol.2014.231 After decades of near neglect, the importance of exercise for patients with Parkinson disease is being increasingly supported by recent studies in experimental animal models and controlled clinical trials. Now, an inverse relationship between physical activity and disease burden has been demonstrated in a large cohort study. Full Text | PDF | |||||||||||||||||||||||||||||||||||||
REVIEWS | Top | ||||||||||||||||||||||||||||||||||||
Disturbed mitochondrial dynamics and neurodegenerative disorders Florence Burté, Valerio Carelli, Patrick F. Chinnery & Patrick Yu-Wai-Man Published online: 09 December 2014 p11 | doi:10.1038/nrneurol.2014.228 The network between mitochondia is in a constant state of flux, with organelles fusing and separating in response to cellular metabolic demands. Disturbances to mitochondrial fusion and fission have been observed in several human diseases, and in this Review, Florence Burté and colleagues discuss how the mitochondrial network might play a crucial part in neurodegeneration. The authors focus on major protein mediators of mitochondrial dynamics, including optic atrophy protein and the mitofusins, and trace the involvement of mitochondrial dynamics in autosomal dominant optic atrophy, Charcot-Marie-Tooth disease and other disorders. Abstract | Full Text | PDF | |||||||||||||||||||||||||||||||||||||
The ongoing pursuit of neuroprotective therapies in Parkinson disease Dilan Athauda & Thomas Foltynie Published online: 02 December 2014 p25 | doi:10.1038/nrneurol.2014.226 Despite the promise that many potential neuroprotective treatments for Parkinson disease (PD) have shown in preclinical studies, the benefits have not been replicated in recent clinical trials. In this Review, Athauda and Foltynie discuss the reasons for this 'failure to translate', and propose strategies to avoid such eventualities in the future, including improved trial design and repositioning of existing drugs. They also review the most promising drugs that are currently in preclinical development or clinical testing for their neuroprotective properties in PD. Abstract | Full Text | PDF | |||||||||||||||||||||||||||||||||||||
Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases Alberto Lleó, Enrica Cavedo, Lucilla Parnetti, Hugo Vanderstichele, Sanna Kaisa Herukka, Niels Andreasen, Roberta Ghidoni, Piotr Lewczuk, Andreas Jeromin, Bengt Winblad, Magda Tsolaki, Barbara Mroczko, Pieter Jelle Visser, Isabel Santana, Per Svenningsson, Kaj Blennow, Dag Aarsland, José Luis Molinuevo, Henrik Zetterberg & Brit Mollenhauer. Published online: 16 December 2014 p41 | doi:10.1038/nrneurol.2014.232 Despite a growing emphasis on biomarkers in research into Alzheimer disease (AD) and Parkinson disease (PD), there is little consensus as to which biomarkers are most effective. In this Review, Lleó and colleagues discuss cerebrospinal fluid (CSF) biomarkers for AD and PD, with a particular emphasis on applicability to clinical trials. Compared with AD, less is known about CSF biomarkers in PD, and the authors highlight several areas for further research. Abstract | Full Text | PDF | Supplementary information | |||||||||||||||||||||||||||||||||||||
PERSPECTIVES | Top | ||||||||||||||||||||||||||||||||||||
OPINION Microglial and macrophage polarization—new prospects for brain repair Xiaoming Hu, Rehana K. Leak, Yejie Shi, Jun Suenaga, Yanqin Gao, Ping Zheng & Jun Chen. Published online: 11 November 2014 p56 | doi:10.1038/nrneurol.2014.207 After brain injuries, microglia and macrophages can aid or hinder tissue repair depending on polarization toward specific cell phenotypes. This Perspectives article describes the phenotypic dynamics and different functions of these cells after acute CNS injury and argues that therapeutic approaches should focus on subtle adjustment of the balance between their phenotypes. Abstract | Full Text | PDF | |||||||||||||||||||||||||||||||||||||
|
*Journal Citation Reports, Thomson, 2013. Nature Reviews Neurology was previously published as Nature Clinical Practice Neurology. |
You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2015 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved. |
No comments:
Post a Comment
Keep a civil tongue.